Amgen launches Amgevita in markets across Europe
Amgen announced that Amgevita, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. Amgevita is the first adalimumab biosimilar to be approved by the European Commission. Amgevita is authorized for the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis; severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; moderate-to-severe hidradenitis suppurativa; non-infectious intermediate, posterior and panuveitis; moderate-to-severe Crohn's disease and moderate-to-severe ulcerative colitis. Amgevita is also authorized for the treatment of pediatric inflammatory diseases, including moderate-to-severe Crohn's disease, severe chronic plaque psoriasis, enthesitis-related arthritis and polyarticular juvenile idiopathic arthritis.